Last updated: August 10, 2026
Ketorolac tromethamine is a mature, low-cost NSAID with commercial opportunities concentrated in formulation engineering rather than new active-ingredient protection. The strongest opportunities are preservative-free ophthalmic products, abuse-resistant or device-enabled nasal delivery, differentiated injection presentations, and excipient systems that improve tolerability, sterility, stability, or administration convenience. API patents are expired, while formulation and method-of-use protection is limited and highly dependent on product design, regulatory pathway, and device integration.
What formulations contain ketorolac tromethamine?
Ketorolac tromethamine is marketed in ophthalmic, injectable, oral, and intranasal dosage forms. The tromethamine salt improves aqueous solubility and supports sterile liquid formulations.
| Dosage form |
Representative product |
Strength |
Primary excipient strategy |
Commercial position |
| Ophthalmic solution |
Acular, Acular LS, generic ketorolac |
0.4% or 0.5% |
Buffering, tonicity, preservative, wetting and viscosity control |
Large generic and post-surgical market |
| Preservative-free ophthalmic solution |
Acular PF and generics |
0.5% |
Single-dose packaging, buffer and tonicity control without BAK |
Premium differentiation |
| Intranasal spray |
Sprix |
15.75 mg per spray |
Buffered isotonic aqueous system, preservative and chelation |
Device-dependent specialty product |
| Injection |
Toradol and generics |
15 or 30 mg/mL |
Aqueous solvent, sodium chloride, pH adjustment, sterile packaging |
Hospital and acute-care use |
| Oral tablet |
Toradol and generics |
10 mg |
Lactose or alternative diluent, disintegrant, binder, lubricant |
Mature generic market |
The FDA-approved products have different risk profiles. Ophthalmic products must control irritation and microbial risk. Intranasal products must manage local tolerability and dose uniformity. Injectable products require sterility, particulate control, container compatibility, and reliable pH control. Tablets face fewer technical barriers but have limited pricing power.
Which excipients are used in ketorolac ophthalmic products?
Ketorolac ophthalmic products typically use excipients for four functions: pH control, isotonicity, wetting, and preservation.
Representative Acular labeling identifies benzalkonium chloride, edetate disodium, octoxynol 40, povidone, sodium chloride, hydrochloric acid, sodium hydroxide, and purified water among the inactive ingredients.[1] The exact formulation varies by strength, manufacturer, and preservative-free status.
| Excipient class |
Representative materials |
Function |
Key development issue |
| Preservative |
Benzalkonium chloride |
Antimicrobial protection in multidose containers |
Ocular-surface toxicity and chronic-use limitations |
| Chelator |
Edetate disodium |
Supports preservative activity and controls trace-metal effects |
Concentration must remain compatible with ocular tolerability |
| Wetting agent |
Octoxynol 40 |
Improves spreading and wetting |
Potential irritation and regulatory acceptability |
| Viscosity or film former |
Povidone |
Improves retention and lubrication |
Excess viscosity can affect drop delivery and vision |
| Tonicity agent |
Sodium chloride |
Approximates tear osmolarity |
Osmolality must be balanced against solubility and comfort |
| pH adjuster |
Hydrochloric acid or sodium hydroxide |
Sets target pH |
Impacts comfort, stability, and preservative performance |
| Buffer |
Citrate, phosphate, or borate systems |
Stabilizes pH |
Buffer capacity can increase irritation |
How can preservative-free ketorolac ophthalmic products be differentiated?
Preservative-free ophthalmic ketorolac is the clearest excipient-led opportunity. Benzalkonium chloride can damage the ocular surface with repeated exposure, particularly in patients with dry eye, corneal disease, glaucoma, or prolonged postoperative treatment. Removing BAK creates a product-development and packaging problem because the formulation loses its multidose antimicrobial protection.
Commercial solutions include:
- Single-dose unit-dose vials.
- Multidose bottles with validated preservative-free dispensing systems.
- Low-surface-area containers that reduce microbial ingress.
- Improved drop-size control to reduce dose waste.
- Lubricating excipient systems using povidone or compatible polymeric agents.
- Reduced-exposure labeling for short postoperative courses.
The most defensible intellectual-property position may reside in the dispensing container, closure system, microbial-control architecture, or combination of formulation and device rather than in the ketorolac composition alone.
What excipient strategy is appropriate for ketorolac nasal spray?
Sprix uses a metered intranasal delivery system that delivers 15.75 mg of ketorolac tromethamine per spray. Its formulation includes an aqueous vehicle with sodium chloride, edetate disodium, benzalkonium chloride, phosphate buffer components, and pH adjustment materials, according to FDA labeling.[2]
The nasal route creates several technical constraints:
- Ketorolac must remain dissolved at the target concentration.
- The formulation must produce consistent spray volume and plume geometry.
- pH and osmolality must limit burning, sneezing, and mucosal irritation.
- The system must remain stable during repeated actuation.
- The pump must prevent leakage, evaporation, and dose drift.
- The container must be compatible with the formulation and preservative.
What commercial opportunities exist in intranasal ketorolac?
A competing product could target the following features:
| Opportunity |
Potential value |
Main barrier |
| Preservative-free nasal spray |
Improved chronic or repeated-use tolerability |
Device microbiology and packaging cost |
| Lower-irritation buffer system |
Better patient acceptance |
Requires comparative clinical evidence |
| Smaller spray volume |
Reduced runoff and swallowing |
May require a higher drug concentration |
| Unit-dose nasal device |
Better sterility control |
Higher cost per administered dose |
| More accurate metered pump |
Lower dose variability |
Device qualification and combination-product testing |
| Alternative mucoadhesive system |
Longer residence time |
Potentially slower onset and more irritation |
| Dual-use emergency packaging |
Improved portability |
Labeling and human-factors requirements |
A 505(b)(2) strategy could be relevant where the developer changes the delivery route, excipient system, device, dose, or administration schedule but relies partly on the established ketorolac reference product. The regulatory burden would depend on the extent of formulation and device changes and on the claims sought.
Which excipients are used in ketorolac injection?
Ketorolac injection is a sterile aqueous formulation. Representative Toradol injection labeling identifies ethanol, sodium chloride, and water for injection, with pH adjustment using hydrochloric acid or sodium hydroxide.[3]
The injectable product has a relatively simple excipient profile, which limits composition-based differentiation. Commercial value is more likely to come from:
- Ready-to-administer presentations.
- Low-volume prefilled syringes.
- Barcoded unit-dose packaging.
- Latex-free and low-extractables components.
- Reduced-overfill containers.
- Compatibility with automated hospital dispensing systems.
- Plastic or polymer container systems with validated ketorolac compatibility.
- Packaging that reduces needlestick or preparation errors.
What manufacturing and container barriers apply to ketorolac injection?
Manufacturers must control:
- Sterility assurance.
- Particulate matter.
- Endotoxin levels.
- Extractables and leachables.
- Adsorption to syringe or tubing materials.
- pH drift during storage.
- Light exposure and temperature excursions.
- Container closure integrity.
Because ketorolac injection is a mature sterile product, manufacturing reliability and hospital procurement economics may matter more than a small excipient change. A prefilled syringe or ready-to-use presentation can create a more credible commercial position than a minor buffer modification.
What tablet excipients are used in ketorolac tromethamine products?
Ketorolac tablets commonly use standard solid-dose excipients such as lactose or another diluent, microcrystalline cellulose, starch or a superdisintegrant, povidone or another binder, and magnesium stearate. The excipient profile varies among ANDA products and should be evaluated against each product’s approved labeling.
Oral tablets offer limited formulation upside because:
- Ketorolac has a short recommended treatment duration.
- The product is available from multiple generic manufacturers.
- Standard excipients are widely available.
- Price competition is substantial.
- Changes to release, bioavailability, or dose may trigger additional regulatory requirements.
Potential niches include lactose-free tablets, orally disintegrating tablets, smaller tablets for swallowing-constrained patients, and unit-dose blister packaging. These opportunities are commercially narrower than preservative-free ophthalmic or device-enabled intranasal products.
When does ketorolac tromethamine lose patent and regulatory exclusivity?
Ketorolac tromethamine has lost primary compound-patent protection. The foundational ketorolac patent family, including U.S. Patent No. 4,089,969, is expired. Generic competition has therefore been established for oral, injectable, and ophthalmic forms.
| Protection category |
Status |
| Active ingredient patent |
Expired |
| Original Toradol exclusivity |
Expired |
| Original ophthalmic exclusivity |
Expired |
| Generic ANDA pathway |
Established |
| Biosimilar pathway |
Not applicable |
| Formulation patent opportunity |
Possible, but narrow and design-dependent |
| Device patent opportunity |
Possible for nasal, preservative-free, or prefilled systems |
| Method-of-use protection |
Possible for specific dosing or treatment claims, subject to validity and enforceability |
Ketorolac is a small molecule, so biosimilar risk does not apply. The relevant competitive risks are ANDA filings, authorized generics, 505(b)(2) products, hospital-contract products, and reformulated delivery systems.
What is the Orange Book status of ketorolac products?
FDA Orange Book listings cover approved drug products and may identify patents and regulatory exclusivities associated with particular reference products.[4] For mature ketorolac products, the commercial landscape is primarily generic. The presence or absence of an active Orange Book listing must be assessed by reference product, dosage form, strength, and current FDA listing status.
The strategic point is that a developer should not assume that an expired API patent creates freedom to launch every differentiated product. A new preservative-free formulation, nasal device, or extended-stability presentation may encounter:
- Active formulation patents.
- Device patents.
- Drug-device combination claims.
- Labeling restrictions.
- Regulatory exclusivity associated with a new clinical use.
- Patent rights held outside the United States.
Which companies are challenging ketorolac patents?
Ketorolac has been subject to extensive generic competition rather than a current, high-value patent challenge cycle comparable to major branded drugs. ANDA applicants have entered after expiration of the principal compound and product protections.
For a new ketorolac product, the relevant challengers would likely include:
- Established ophthalmic generic manufacturers.
- Injectable generic manufacturers.
- Hospital-focused pharmaceutical suppliers.
- Specialty companies with nasal or ocular delivery platforms.
- Contract manufacturers offering private-label products.
- International manufacturers entering through country-specific registrations.
Paragraph IV risk is most relevant if a new product relies on a later-issued formulation, device, or method-of-use patent. The commercial impact would depend on whether the challenged claims cover the product as marketed or only a narrow implementation.
How strong is the ketorolac patent estate?
The baseline ketorolac patent estate is weak because the compound and original products are long off-patent. New protection can be meaningful only when it covers a technically difficult and commercially relevant feature.
| Patent subject |
Relative strength |
Why |
| Ketorolac molecule or salt |
Low |
Core protection has expired |
| Routine tablet excipients |
Low |
Easy design-around and limited technical differentiation |
| Standard injectable vehicle |
Low |
Mature, conventional formulation |
| Preservative-free ophthalmic composition |
Moderate |
Can address tolerability and stability, but alternatives are available |
| Multidose preservative-free container |
Moderate to high |
Device and microbiological barriers can increase switching costs |
| Nasal pump and dose-control system |
Moderate to high |
Combination-product and human-factors complexity |
| Specific low-irritation formulation |
Moderate |
Requires evidence and may have multiple substitutes |
| New clinical dosing regimen |
Variable |
Dependent on claim scope, enablement, and infringement facts |
The strongest patent strategy combines a narrow formulation claim with a container, pump, manufacturing process, or dosing regimen. A composition claim based solely on commonly used excipients is more vulnerable to invalidity and design-around arguments.
What patent litigation affects ketorolac commercial opportunities?
The main litigation exposure for a new entrant would arise from formulation and device patents, not from the expired compound patent. Key disputes could involve:
- Whether the accused product contains the claimed buffer or preservative system.
- Whether a nasal pump meets claimed dose-volume or plume parameters.
- Whether a preservative-free package performs the claimed microbial-control function.
- Whether a label induces use within a patented method.
- Whether a manufacturing process is practiced by the contract manufacturer.
- Whether the product falls within an Orange Book-listed claim.
Settlement agreements are less likely to produce major market exclusions for basic ketorolac tablets or injections because the products are commoditized. A settlement could have greater value for a differentiated nasal or ophthalmic product if the patent holder controls a commercially relevant device or formulation.
What FDA regulatory pathways apply to new ketorolac products?
ANDA pathway
An ANDA is appropriate for a product that demonstrates sameness to a reference listed drug in dosage form, strength, route, active ingredient, and relevant performance characteristics. It is generally the lowest-risk route for standard ketorolac tablets, injections, and ophthalmic solutions.
505(b)(2) pathway
A 505(b)(2) application may be appropriate for:
- A new route of administration.
- A new nasal or ocular delivery device.
- A preservative-free multidose presentation.
- A materially different excipient system.
- A new dosage regimen.
- A new clinical use supported partly by existing ketorolac data.
A 505(b)(2) product may obtain three years of exclusivity for certain new clinical investigations, but that exclusivity does not create broad molecule-level protection.
Combination-product considerations
Nasal sprays, prefilled syringes, and specialized ophthalmic dispensers may be drug-device combination products. Product development must cover device performance, extractables, microbial ingress, dose uniformity, usability, and container closure integrity.
What are the best commercial opportunities for ketorolac excipients?
1. Preservative-free ophthalmic ketorolac
This is the strongest formulation opportunity. Demand is supported by ocular-surface tolerability concerns and postoperative use. The value proposition is clearest when combined with a reliable multidose preservative-free dispenser or convenient unit-dose packaging.
2. Low-irritation intranasal ketorolac
A formulation with improved nasal comfort, lower runoff, or better spray uniformity could compete against standard intranasal ketorolac. Clinical evidence would be needed to support claims beyond simple equivalence.
3. Ready-to-administer injection
Prefilled syringes and unit-dose products can reduce preparation steps in hospitals. The excipient system itself may remain conventional, while the commercial differentiation comes from packaging, stability, and workflow integration.
4. Specialized ophthalmic lubricity systems
Povidone and other compatible polymers can improve ocular retention and comfort. The formulation must avoid excessive viscosity, blurred vision, drop-size inconsistency, and incompatibility with the preservative or container.
5. Excipient supply and CDMO services
Suppliers can capture value through:
- Low-endotoxin excipient grades.
- Sterile fill-finish services.
- Preservative-free packaging.
- Nasal pump qualification.
- Stability-indicating analytical methods.
- Container compatibility studies.
- Formulation screening for pH, osmolality, viscosity, and spray performance.
How does ketorolac compare with competing NSAID products?
| Product category |
Ketorolac advantage |
Competitive weakness |
Excipient opportunity |
| Ibuprofen tablets |
Strong acute analgesic positioning |
More limited treatment duration and safety constraints |
Low |
| Diclofenac ophthalmic |
Established ocular use |
Competing clinical positioning |
Moderate |
| Nepafenac ophthalmic |
Prodrug and postoperative positioning |
Higher product cost |
Moderate |
| Bromfenac ophthalmic |
Longer dosing convenience |
Branded and generic competition |
Moderate |
| Injectable opioids |
Non-opioid mechanism |
NSAID renal, gastrointestinal, and bleeding risks |
Low to moderate |
| Intranasal opioids |
Non-opioid route option |
Nasal irritation and dosing limitations |
Moderate |
Ketorolac’s commercial advantage is strongest where non-opioid analgesia, rapid onset, and local delivery are valued. Its principal limitation is the restricted duration of systemic use and the associated renal, gastrointestinal, and bleeding risks identified in FDA labeling.[3,5]
What generic launch risks exist for new ketorolac products?
A new entrant faces four principal risks:
- Generic substitution for standard strengths and dosage forms.
- Rapid price erosion after ANDA approval.
- Limited physician incentive to switch absent a meaningful tolerability or workflow benefit.
- Easy design-around of narrow excipient claims.
Launch economics improve when the product has a differentiated package, exclusive channel, hospital formulary advantage, or clinically meaningful preservative-free or device-enabled feature. A conventional tablet with a new filler is unlikely to support premium pricing.
Key Takeaways
- Ketorolac tromethamine’s compound patent protection is expired.
- Biosimilar risk does not apply because ketorolac is a small molecule.
- Standard tablets and injections are mature generic markets with limited excipient differentiation.
- Preservative-free ophthalmic ketorolac offers the strongest formulation opportunity.
- Nasal spray performance, pump accuracy, and local tolerability can support a differentiated product.
- Prefilled injectable presentations can create hospital workflow and packaging value.
- The most defensible new patent claims are likely to cover formulation-device combinations, microbial-control systems, spray delivery, or specific manufacturing processes.
- FDA pathway selection should distinguish conventional ANDA products from materially changed 505(b)(2) formulations.
- Revenue exposure is concentrated in product differentiation and channel strategy because API-level exclusivity no longer protects pricing.
FAQs
Is ketorolac tromethamine a good candidate for a preservative-free formulation?
Yes. Preservative-free ophthalmic ketorolac has a clear rationale for patients exposed to repeated topical dosing or at risk of ocular-surface irritation. The principal technical challenge is maintaining sterility through the container and dispensing system.
Can a new excipient combination extend ketorolac patent protection?
A new excipient combination may support a formulation patent if it produces a specific, non-obvious technical result. Routine substitutions among common buffers, tonicity agents, or lubricants are more vulnerable to obviousness and design-around challenges.
Does ketorolac tromethamine require a biosimilar application?
No. Ketorolac tromethamine is a chemically synthesized small molecule. Generic products use the ANDA pathway, while materially different delivery systems may use 505(b)(2).
Which ketorolac dosage form has the highest commercial differentiation potential?
Preservative-free ophthalmic products and device-enabled intranasal products have greater differentiation potential than conventional tablets. Their value depends on tolerability, delivery consistency, packaging, and clinical positioning.
Are ketorolac excipients subject to FDA approval?
Excipients must be suitable for the intended route, dose, and formulation. FDA review considers safety, prior use, quality, impurities, compatibility, and manufacturing controls. Inclusion in the FDA Inactive Ingredient Database can support regulatory strategy but does not automatically establish approval for every route or concentration.[6]
References
-
U.S. Food and Drug Administration. (2023). Acular (ketorolac tromethamine ophthalmic solution) prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2023). Sprix (ketorolac tromethamine nasal spray) prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2023). Toradol (ketorolac tromethamine injection) prescribing information. DailyMed.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Ketorolac tromethamine labeling and safety information. FDA.
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
-
U.S. Patent No. 4,089,969. (1978). Heterocyclic compounds. U.S. Patent and Trademark Office.
